GO:0051059 NF-kappaB binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051059 (NF-kappaB binding) describes the molecular function of selectively binding to NF-kappaB, a eukaryotic RNA polymerase II promoter transcription factor.
• NF-kappaB DNA-binding specificity is dictated by dimer composition, post-translational modifications, and interaction partners, not by a single consensus sequence.
• Non-canonical regulators such as hnRNP UL1, NrCAM, YAP, and ABIN proteins modulate NF-kappaB binding and downstream inflammatory or oncogenic outputs.
• IKK docking to NF-kappaB substrates is a prerequisite for signal-induced phosphorylation and subsequent activation.
• Dysregulated NF-kappaB binding is mechanistically linked to brain tumor development, autoimmune inflammation, Graves' disease, and clear cell renal cell carcinoma.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of NF-kappaB binding events in disease-relevant cell types.
Description
NF-kappaB binding (GO:0051059) is a molecular function defined as binding to NF-kappaB, a transcription factor for eukaryotic RNA polymerase II promoters. NF-kappaB proteins are dimeric transcription factors whose DNA-binding activity is specified by subunit composition, sequence context, and interacting cofactors. Because NF-kappaB controls hundreds of target genes, the precise binding events that occur at promoters and enhancers determine whether cells mount inflammatory, survival, or proliferative transcriptional programs. Researchers study GO:0051059 to understand how upstream signals are converted into selective gene expression and how this selectivity is corrupted in disease. Recent work has expanded the repertoire of NF-kappaB-binding proteins beyond canonical I-kappaB inhibitors to include RNA-binding proteins, cell-adhesion molecules, Hippo pathway effectors, and ubiquitin-binding adaptors. These discoveries position NF-kappaB binding as a central node for therapeutic intervention in cancer, autoimmunity, and metabolic disease.
NF-kappaB binding At A Glance
| GO ID | GO:0051059 |
|---|---|
| GO term | NF-kappaB binding |
| Ontology | molecular_function |
| Synonym | None |
| Definition | Binding to NF-kappaB, a transcription factor for eukaryotic RNA polymerase II promoters. |
| Major function | Mediates selective protein-protein interactions that regulate NF-kappaB localization, DNA occupancy, and transcriptional output. |
| Representative partners | I-kappaB proteins, ABIN proteins, hnRNP UL1, NrCAM, YAP, IKK subunits. |
| Disease relevance | Cancer, autoimmunity, inflammatory disorders, Graves' disease. |
| Research methods | CRISPR KO/point mutation/KI/overexpression, co-IP, ChIP-seq, reporter assays, proteomics. |
What Is GO:0051059?
GO:0051059 (NF-kappaB binding) is the molecular function of selectively and non-covalently interacting with NF-kappaB, a transcription factor that regulates eukaryotic RNA polymerase II promoters. This term captures binding events that may stabilize, inhibit, or redirect NF-kappaB activity, including interactions with inhibitor proteins, adaptors, and non-canonical partners.
Why Is NF-kappaB binding Important in Cell Biology?
NF-kappaB binding is important because it determines which NF-kappaB dimers engage which genomic loci and how long they remain there, thereby shaping inflammatory, immune, and survival gene programs. Disruption of these binding events is directly implicated in tumorigenesis, autoimmune inflammation, and metabolic reprogramming.
• Defines the selectivity of NF-kappaB target gene activation in response to diverse stimuli.
• Controls inflammatory cytokine production through proteins such as hnRNP UL1 that bind kappaB sites.
• Regulates Th17 cell differentiation in autoimmune contexts such as Graves' disease.
• Modulates tumor growth in clear cell renal cell carcinoma via YAP-TEAD-NF-kappaB complexes.
• Links metabolic signals such as alpha-ketoglutarate to NF-kappaB activation in brain tumors.
• Provides a mechanistic basis for IKK substrate docking and phosphorylation.
• Enables ubiquitin-dependent inhibition of NF-kappaB by ABIN proteins.
• Offers druggable interfaces for anti-inflammatory and anti-cancer strategies.
• Supports biomarker discovery through binding-partner profiling.
• Underpins CRISPR-based functional genomics of immune and cancer pathways.
Molecular Mechanism of NF-kappaB binding
Dimer Specification and DNA Binding Activity
In simple terms: Different NF-kappaB subunit combinations recognize different DNA sequences.
NF-kappaB DNA-binding activity is specified by dimer composition and sequence context, meaning that RelA, RelB, c-Rel, NFKB1, and NFKB2 pairings produce distinct binding preferences. This specification determines which promoters and enhancers are occupied and is a foundational concept for interpreting GO:0051059.
Non-canonical Binding Partners at kappaB Sites
In simple terms: Proteins other than the classical inhibitors can bind NF-kappaB or kappaB sites.
The RNA-binding protein hnRNP UL1 binds kappaB sites and attenuates NF-kappaB-mediated inflammation, illustrating that GO:0051059 encompasses non-canonical nucleic-acid-associated partners. NrCAM competitively binds SUMO-1 and activates NF-kappaB signaling, further expanding the interaction landscape.
Competitive and Structural Regulation by Effectors
In simple terms: Some proteins block or reshape NF-kappaB complexes by competing for partners.
YAP represses the TEAD-NF-kappaB complex and inhibits clear cell renal cell carcinoma growth, showing that competition for NF-kappaB binding can suppress tumorigenesis. ABIN proteins use ubiquitin binding to mediate their NF-kappaB inhibitory potential, linking ubiquitin recognition to GO:0051059.
IKK Docking and Substrate Phosphorylation
In simple terms: The IKK kinase must dock onto NF-kappaB substrates before it can modify them.
The molecular mechanism of IKK catalytic dimer docking to NF-kappaB substrates reveals that binding precedes phosphorylation and activation. This docking step is a prerequisite for signal-induced NF-kappaB activation and is a key regulatory node within GO:0051059.
Metabolic Coupling to NF-kappaB Activation
In simple terms: Metabolites can influence how NF-kappaB is activated.
alpha-Ketoglutarate-activated NF-kappaB signaling promotes compensatory glucose uptake and brain tumor development, demonstrating that metabolic cues feed into NF-kappaB binding and activation. This coupling highlights the integration of cellular metabolism with GO:0051059.
Key Genes Involved in GO:0051059 NF-kappaB binding
The following genes and proteins represent major players in NF-kappaB binding (GO:0051059) and its regulatory network.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NFKB1 | Forms p50-containing NF-kappaB dimers that bind DNA | Core subunit for GO:0051059 studies |
| NFKB2 | Forms p52-containing dimers with distinct binding specificity | Dimer-specific DNA binding |
| RELA | Primary transactivating subunit of canonical NF-kappaB | Central to inflammatory gene activation |
| RELB | Non-canonical NF-kappaB subunit | Alternative pathway binding |
| REL | c-Rel subunit with immune-specific functions | Lymphoid gene regulation |
| NFKBIA | I-kappaB alpha inhibitor that binds and retains NF-kappaB | Classical GO:0051059 interaction |
| NFKBIB | I-kappaB beta inhibitor | Cytoplasmic sequestration |
| ABIN1 | Ubiquitin-binding inhibitor of NF-kappaB | Ubiquitin-dependent inhibition |
| ABIN2 | Adaptor with NF-kappaB inhibitory potential | Ubiquitin binding |
| ABIN3 | NF-kappaB inhibitory protein | Ubiquitin binding |
| HNRNPUL1 | RNA-binding protein that binds kappaB sites | Attenuates inflammation |
| NRCAM | Cell adhesion molecule that binds SUMO-1 and activates NF-kappaB | Th17 differentiation in Graves' disease |
| YAP1 | Hippo effector that represses TEAD-NF-kappaB complex | ccRCC tumor suppression |
| IKBKB | IKK beta kinase that docks onto NF-kappaB substrates | Substrate phosphorylation |
| IKBKA | IKK alpha kinase subunit | Non-canonical signaling |
| IKBKG | NEMO regulatory subunit of IKK | Docking and activation |
| SUMO1 | Small ubiquitin-like modifier competed for by NrCAM | Modulates NF-kappaB activation |
How Is NF-kappaB binding Regulated?
NF-kappaB binding is regulated at multiple levels, including dimer composition and DNA sequence specificity, post-translational modification and inhibitor interactions, competitive binding by effectors such as YAP and NrCAM, ubiquitin-dependent inhibition by ABIN proteins, and metabolic inputs such as alpha-ketoglutarate. IKK docking to NF-kappaB substrates provides an additional regulatory checkpoint that couples upstream signals to binding and activation.
NF-kappaB binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NFKB1 | Inflammatory and immune disorders | Knockout cell lines and reporter assays |
| HNRNPUL1 | Autoimmune inflammation | Overexpression and knockdown in immune cells |
| NRCAM | Graves' disease and Th17 differentiation | Knockout T cell models |
| YAP1 | Clear cell renal cell carcinoma | Knockout and overexpression in ccRCC lines |
| ABIN1 | NF-kappaB-driven inflammatory disease | Point-mutation and knockout models |
NF-kappaB Binding in Brain Tumors
alpha-Ketoglutarate-activated NF-kappaB signaling promotes compensatory glucose uptake and brain tumor development, directly linking metabolic regulation of NF-kappaB binding to oncogenesis. This suggests that targeting NF-kappaB binding events may disrupt tumor metabolic adaptation.
NF-kappaB Binding in Autoimmune Inflammation
hnRNP UL1 binds kappaB sites to attenuate NF-kappaB-mediated inflammation, indicating that non-canonical NF-kappaB-binding proteins can dampen autoimmune pathology. NrCAM activates NF-kappaB signaling by competitively binding SUMO-1 and promotes Th17 cell differentiation in Graves' disease, highlighting a role in autoimmune thyroid disease.
NF-kappaB Binding in Renal Cell Carcinoma
YAP represses the TEAD-NF-kappaB complex and inhibits the growth of clear cell renal cell carcinoma, demonstrating that disrupting NF-kappaB binding complexes can suppress tumor growth. This positions GO:0051059 as a potential therapeutic axis in ccRCC.
From NF-kappaB binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene alter NF-kappaB DNA binding? | CRISPR knockout cell line |
| Does a specific residue mediate NF-kappaB interaction? | CRISPR point-mutation knock-in |
| Can a tag be used to track NF-kappaB binding complexes? | Tagged knock-in |
| Does overexpression of a partner enhance NF-kappaB activation? | CRISPR overexpression |
| Which genes regulate NF-kappaB binding genome-wide? | CRISPR library screening |
| What pathways are enriched among NF-kappaB binding regulators? | Bioinformatics analysis |
How to Study the NF-kappaB binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ChIP-seq | Genome-wide NF-kappaB DNA occupancy | Mapping binding sites |
| Co-IP / mass spectrometry | Protein-protein interactions | Identifying binding partners |
| Luciferase reporter | Transcriptional activity | Functional validation |
| RNA-seq | Global gene expression changes | Pathway analysis |
| CRISPR knockout | Loss-of-function effects | Causal gene testing |
| CRISPR point mutation | Residue-specific function | Dissecting binding interfaces |
| CRISPR knock-in | Tagged or reporter alleles | Tracking endogenous complexes |
| Bioinformatics | Pathway and network enrichment | Data integration |
Chromatin Immunoprecipitation and Sequencing
ChIP-seq measures genome-wide occupancy of NF-kappaB dimers and associated factors, providing direct readouts of GO:0051059 at specific loci.
Co-immunoprecipitation and Proteomics
Co-IP coupled with mass spectrometry identifies binding partners of NF-kappaB subunits, revealing non-canonical interactors such as hnRNP UL1 and NrCAM.
Reporter Assays and Transcriptomics
Luciferase reporters and RNA-seq quantify transcriptional consequences of altered NF-kappaB binding, linking molecular function to gene expression programs.
CRISPR Functional Genomics
CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of candidate genes in NF-kappaB binding pathways.
How CRISPR Can Be Used to Study GO:0051059 NF-kappaB binding
Knockout
CRISPR knockout of candidate genes such as NFKB1, HNRNPUL1, or YAP1 enables loss-of-function assessment of their contribution to NF-kappaB binding and downstream transcription.
Point Mutation
Point mutations introduced at residues mediating NF-kappaB interaction, such as those in IKK docking interfaces, allow precise dissection of binding mechanisms.
Knock-in
Knock-in of epitope tags or fluorescent reporters at endogenous loci facilitates tracking of NF-kappaB binding complexes in live cells.
Overexpression
CRISPR-mediated overexpression of partners such as NrCAM or ABIN proteins tests sufficiency for modulating NF-kappaB binding and signaling.
How EDITGENE Supports NF-kappaB binding Research
Researchers studying NF-kappaB binding-related genes often need to determine whether a candidate gene is causally involved in binding, activation, or downstream transcription. EDITGENE provides end-to-end CRISPR cell model generation and screening services to accelerate this causal dissection.
Contact EDITGENE today to design your custom CRISPR model for NF-kappaB binding research.
Frequently Asked Questions About NF-kappaB binding
What is GO:0051059 NF-kappaB binding?
GO:0051059 is a molecular function term describing binding to NF-kappaB, a transcription factor for eukaryotic RNA polymerase II promoters.
What genes are involved in NF-kappaB binding?
Key genes include NFKB1, NFKB2, RELA, RELB, REL, NFKBIA, ABIN1, HNRNPUL1, NRCAM, YAP1, and IKK subunits.
How is NF-kappaB DNA binding specificity determined?
Specificity is specified by dimer composition, sequence context, and post-translational modifications.
What diseases are linked to NF-kappaB binding?
Brain tumors, autoimmune inflammation, Graves' disease, and clear cell renal cell carcinoma are linked to altered NF-kappaB binding.
How can I study NF-kappaB binding in the lab?
ChIP-seq, co-IP, reporter assays, RNA-seq, and CRISPR models are commonly used.
What is the role of IKK in NF-kappaB binding?
IKK catalytic dimers dock onto NF-kappaB substrates to enable phosphorylation and activation.
Can CRISPR knockout help study NF-kappaB binding?
Yes, knockout of candidate genes enables loss-of-function assessment of NF-kappaB binding and downstream effects.
What is the role of ubiquitin in NF-kappaB binding?
ABIN proteins use ubiquitin binding to mediate NF-kappaB inhibition.
How does metabolism affect NF-kappaB binding?
alpha-Ketoglutarate activates NF-kappaB signaling and promotes glucose uptake in brain tumors.
What services does EDITGENE offer for NF-kappaB binding research?
EDITGENE offers knockout, point-mutation, knock-in, overexpression, library screening, and bioinformatics services.
Conclusion
GO:0051059 (NF-kappaB binding) is a central molecular function that governs how NF-kappaB dimers and their partners select genomic targets and drive context-specific transcription. Its dysregulation contributes to cancer, autoimmunity, and metabolic disease, making it a high-value target for mechanistic and therapeutic research. CRISPR-based cell models and functional genomics provide powerful tools to dissect these binding events with causal precision.
References
- 1. Wang X et al.. 2019. α-Ketoglutarate-Activated NF-κB Signaling Promotes Compensatory Glucose Uptake and Brain Tumor Development.. Mol Cell 76(1):148-162.e7 PMID: 31447391
- 2. Wan F et al.. 2009. Specification of DNA binding activity of NF-kappaB proteins.. Cold Spring Harb Perspect Biol 1(4):a000067 PMID: 20066093
- 3. Williams LM et al.. 2020. Looking Down on NF-κB.. Mol Cell Biol 40(15) PMID: 32393609
- 4. Ma Z et al.. 2022. RNA-binding protein hnRNP UL1 binds κB sites to attenuate NF-κB-mediated inflammation.. J Autoimmun 129:102828 PMID: 35429914
- 5. Huang F et al.. 2024. NrCAM activates the NF-κB signalling pathway by competitively binding to SUMO-1 and promotes Th17 cell differentiation in Graves' disease.. Scand J Immunol 100(5):e13401 PMID: 39155774
- 6. Li Z et al.. 2024. YAP represses the TEAD-NF-κB complex and inhibits the growth of clear cell renal cell carcinoma.. Sci Signal 17(843):eadk0231 PMID: 38954637
- 7. Li C et al.. 2024. Molecular mechanism of IKK catalytic dimer docking to NF-κB substrates.. Nat Commun 15(1):7692 PMID: 39227404
- 8. Wagner S et al.. 2008. Ubiquitin binding mediates the NF-kappaB inhibitory potential of ABIN proteins.. Oncogene 27(26):3739-45 PMID: 18212736
